| Catalog No. | DB681018 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 0.156 μg/ml |
|---|
| Range | 0.31-5 μg/mL |
|---|
| Accession |
P29320 |
| Applications |
ELISA |
| Detection method |
Colorimetric |
| Assay type |
Quantitative |
| Recovery |
80-120% |
| Shipping |
2-8 ℃ |
| Stability and Storage |
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Specifications |
Ifabotuzumab
|
| Alternate Names | Fibatuzumab, KB-004, , 1234137-51-9 |
|---|
| Background | Ifabotuzumab (formerly KB004) is a first-in-class therapeutic non-fucosylated IgG1 (human f-allotype) monoclonal antibody being developed by Humanigen (formerly KaloBios Pharmaceuticals) for the treatment of cancer. The drug was licensed from the Ludwig Institute for Cancer Research. The molecule contains a human antibody constant region with V-regions that are 92% identical to human germ-line sequences. Ifabotuzumab targets the ephrin type-A receptor 3 (EphA3) tyrosine kinase. In non-clinical studies, Ifabotuzumab demonstrated potent ex-vivo cell killing of EphA3+ tumor cells obtained from patients with hematologic malignancies. |
|---|
| Note |
For Research Use Only. |
